Jove
Visualize
Contact Us

Related Experiment Videos

Anti-HIV drug update

    Project Inform Perspective
    |August 13, 2002
    PubMed
    Summary

    New anti-HIV drugs are advancing, with research optimizing protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Studies now explore dual NNRTI combinations for improved HIV treatment strategies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Pharmacology
    • Virology
    • Drug Development

    Background:

    • Ongoing advancements in anti-HIV drug development are crucial for managing the human immunodeficiency virus (HIV) epidemic.
    • Optimizing existing drug classes, such as protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), is a key strategy.

    Discussion:

    • Research is exploring various combination therapies to enhance antiviral efficacy and overcome drug resistance.
    • This includes evaluating dual protease inhibitor regimens, combined protease inhibitor and NNRTI therapies, and novel dual NNRTI combinations.

    Key Insights:

    • The focus is shifting towards more complex combination strategies to improve treatment outcomes for HIV patients.
    • Dual NNRTI combinations represent a new frontier in optimizing antiretroviral therapy.

    Outlook:

    • Further clinical trials are needed to establish the safety and efficacy of these novel drug combinations.
    • These advancements hold promise for more effective and potentially simplified HIV treatment regimens in the future.

    Related Experiment Videos